ASIANET: PHARMACIA & UPJOHN LAUNCHES NEW NICORETTE INHALER

ข่าวต่างประเทศ Monday September 9, 1996 10:18 —Asianet Press Release

PHARMACIA & UPJOHN LAUNCHES NEW NICORETTE INHALER NOW THE STEP AWAY FROM CIGARETTES IS EVEN SHORTER FRESH HOPE FOR DISCONTENTED SMOKERS HELSINGBORG, Sweden, Sept. 6 /PRNewswire - AsiaNet/ -- Pharmacia & Upjohn Inc. (NYSE: PNU), a world leader in nicotine replacement therapy (NRT), today launched the Nicorette Inhaler, the world's first inhaler-based drug delivery system for smoking cessation, which will be sold as an over the counter (OTC) pharmaceutical product for smokers in Denmark. The Danish launch is the first of a series of launches planned through Europe and worldwide. Nicorette Inhaler is a unique addition to the Nicorette range of products in addressing both the physical and behavioral aspects of nicotine dependence. The step away from cigarettes is made shorter than with other NRT products by providing a high degree of behavioral replacement for the majority of smokers who are dependent on the rituals of smoking. At the same time, Nicorette Inhaler provides pure nicotine (without carbon monoxide and tar) in amounts lower than smoking but adequate to relieve the physical craving for nicotine. Nicorette Inhaler is the result of many years of development following acquisition of the technology from the U.S. company, Advanced Therapeutic Products (ATP), in 1987. Registration as a pharmaceutical product required development of new manufacturing techniques to provide a consistent quality product with established efficacy and safety. To date, six clinical trials involving 1440 smokers have demonstrated that Nicorette Inhaler is safe and effective in relieving withdrawal symptoms and helping smokers quit. Nicotine release is controlled by inhaling air through a mouthpiece (either with shallow or deep puffing) which contains a cartridge loaded with a nicotine impregnated plug. The air becomes saturated with vaporized nicotine which is then mainly absorbed through the lining of the mouth. The mouthpiece and cartridges are available with a reclosable plastic container for carrying convenience. "As pressure on smokers to quit builds across the world, the need increases for effective products," said Karl Olov Fagerstrom, Director for Scientific Information, Pharmacia & Upjohn. "Motivation is necessary but not enough in many cases. The nicotine and behavioral dependencies are the obstacles that can be reduced with the Nicorette Inhaler. You have none of the cancer and respiratory disease risks associated with smoking." "Nicorette Inhaler will be our next major product to help people enjoy life without cigarettes. Thanks to its unique properties, it is expected to gain high acceptance from smokers," said Arne Nordstrom, Vice President for Strategic Product Management NRT at Pharmacia & Upjohn. "As a valuable complement to our product range, we expect that the Nicorette Inhaler will attract new customers and provide the biggest growth in the NRT market since the launch of nicotine patches. Market research has been extremely encouraging with up to 50% of smokers expressing an interest in product trial. The world NRT market is currently estimated at $500 million." "Denmark is important because it is the first country in the world to launch the Nicorette Inhaler. The prevalence of smoking in the population is high, and smokers have been receptive to NRT. We have a strong market presence, and this is an ideal country for the inaugural launch of Nicorette Inhaler. Other launches are expected, following regulatory approvals. In addition to Denmark, the product has been approved in Italy and the Netherlands." Pharmacia & Upjohn, Inc., is a research-based pharmaceutically focused company dedicated to helping people around the world live longer and fuller lives. The company was formed through a merger of Pharmacia AB and The Upjohn Company and began operating in November 1995. Pharmacia & Upjohn is a provider of human health care and related products, and operates on a global basis. The company has a corporate management center in London and major research and manufacturing centers in the United States, Sweden and Italy. CONTACT: Dr. Karl Olov Fagerstrom, Director Scientific Information NRT, Pharmacia & Upjohn, Consumer Healthcare, 46-42-28-84-58, Arne Nordstrom, VP Strategic Product Management NRT, Pharmacia & Upjohn, Consumer Healthcare, 46-42-28-84-56, or Mobile (GSM), 46-70-592-9400, or Christina Falk, Manager Communications, Pharmacia & Upjohn, Consumer Healthcare, Phone: 46-42-28-87-46, or Mobile (GSM), 46-70-543-7450

แท็ก ADVANC   mobile   asian   AFET   GIS   tat  

เว็บไซต์นี้มีการใช้งานคุกกี้ ศึกษารายละเอียดเพิ่มเติมได้ที่ นโยบายความเป็นส่วนตัว และ ข้อตกลงการใช้บริการ รับทราบ